Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · August 28, 2023

Hepcidin Level and Iron Status in Patients With IBD Undergoing Induction Therapy With Vedolizumab or Infliximab

Inflammatory Bowel Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
Inflamm. Bowel Dis. 2023 Aug 01;29(8)1272-1284, R Loveikyte, AR Bourgonje, JJ van der Reijden, MLC Bulthuis, LJAC Hawinkels, MC Visschedijk, EAM Festen, HM van Dullemen, RK Weersma, H van Goor, AE van der Meulen-de Jong, G Dijkstra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading